A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD in Cystic Fibrosis Patients With at Least 1 G542X Allele

NCT04126473 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
17
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Eloxx Pharmaceuticals, Inc.